NASDAQ:CMRX - Chimerix Stock Price, Forecast & News

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix Inc (NASDAQ:CMRX) announced its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. The biopharmaceutical company earned $1.96 million during the quarter, compared to the consensus estimate of $1.30 million. Chimerix had a negative net margin of 1,162.96% and a negative return on equity of 38.75%. View Chimerix's Earnings History.

Chimerix is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Chimerix.

3 analysts have issued 1 year target prices for Chimerix's stock. Their forecasts range from $2.00 to $7.00. On average, they anticipate Chimerix's stock price to reach $4.00 in the next year. This suggests a possible upside of 127.3% from the stock's current price. View Analyst Price Targets for Chimerix.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.

News coverage about CMRX stock has trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chimerix earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Chimerix.

Chimerix saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 853,700 shares, a decrease of 27.0% from the January 15th total of 1,170,000 shares. Based on an average daily volume of 721,100 shares, the days-to-cover ratio is presently 1.2 days. Currently, 1.9% of the company's shares are sold short. View Chimerix's Current Options Chain.

Some companies that are related to Chimerix include Avedro (AVDR), Progenics Pharmaceuticals (PGNX), Cue Biopharma (CUE), Mirum Pharmaceuticals (MIRM), Verrica Pharmaceuticals (VRCA), Avid Bioservices (CDMO), Mallinckrodt (MNK), DURECT (DRRX), Mersana Therapeutics (MRSN), Rigel Pharmaceuticals (RIGL), Calithera Biosciences (CALA), Corbus Pharmaceuticals (CRBP), Kindred Biosciences (KIN), Lannett (LCI) and Urovant Sciences (UROV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Wynn Resorts (WYNN), SLS International (SLS), Gilead Sciences (GILD), Walmart (WMT) and TherapeuticsMD (TXMD).

Chimerix's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.81%), State Street Corp (1.99%), AQR Capital Management LLC (1.70%), Acadian Asset Management LLC (1.38%), UBS Group AG (0.95%) and Jacobs Levy Equity Management Inc. (0.94%). Company insiders that own Chimerix stock include Ernest Mario, Fred A Middleton, Garrett Nichols, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View Institutional Ownership Trends for Chimerix.

CMRX stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Alambic Investment Management L.P., Goldman Sachs Group Inc., Bank of America Corp DE, Man Group plc and Rhumbline Advisers. View Insider Buying and Selling for Chimerix.

CMRX stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Renaissance Technologies LLC, Panagora Asset Management Inc., Acadian Asset Management LLC, Ikarian Capital LLC, State Street Corp, Jacobs Levy Equity Management Inc. and AJO LP. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View Insider Buying and Selling for Chimerix.

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CMRX stock can currently be purchased for approximately $1.76.

Chimerix has a market capitalization of $108.03 million and generates $7.22 million in revenue each year. The biopharmaceutical company earns $-69,470,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 82 workers across the globe.View Additional Information About Chimerix.

The official website for Chimerix is http://www.chimerix.com/.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]